Leap Therapeutics Inc

LPTX

Company Profile

  • Business description

    Leap Therapeutics Inc is a biopharmaceutical company developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways, targeting cancer-specific cell surface molecules, and harnessing the immune system to attack cancer cells. The company's key clinical-stage drug candidate is sirexatamab (DKN-01), which targets Dickkopf-related protein 1 (DKK1) and is being studied in a clinical trial in patients with colorectal cancer. In addition, it also has a preclinical program to develop a proprietary monoclonal antibody, called FL-501 which works by inhibiting the GDF-15 protein.

  • Contact

    47 Thorndike Street
    Suite B1-1
    CambridgeMA02141
    USA

    T: +1 617 714-0360

    E: [email protected]

    https://www.leaptx.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    52

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,797.2031.50-0.36%
CAC 407,766.7143.240.56%
DAX 4024,206.91133.240.55%
Dow JONES (US)44,240.76165.60-0.37%
FTSE 1008,854.1847.650.54%
HKSE24,148.07260.241.09%
NASDAQ20,418.465.950.03%
Nikkei 22539,769.4880.670.20%
NZX 50 Index12,752.95106.07-0.82%
S&P 5006,225.524.46-0.07%
S&P/ASX 2008,559.0031.70-0.37%
SSE Composite Index3,497.4824.350.70%

Market Movers